invest summari reiter ow rate price target
share post beat ahead expect
strong year oper compani given durabl busi model
macro tailwind think multipl hold upward earn
revis drive share higher think multipl support
durabl busi model macro tailwind solid execut upward
earn revis could come higher-than-anticip peak sale new
launch better-than-expect oper margin improv
posit quarter support thesi report
oper growth revenu oper growth adjust net
incom report sale factset
grow industri growth continu
build strateg invest plan support growth core
busi evolv space diagnost devic digit data
analyt full year expect oper growth
revenu adjust net incom receiv approv
 canada revolut new combin topic product
cat kitten provid parasit protect flea tick ear mite
roundworm hookworm heartworm continu bring new
canin product addit market cytopoint simparica receiv
addit approv countri asia east see
opportun margin expans beyond monoclon antibodi
pain tripl combo could blockbust product
report ep factset consensu
higher estim present ep guidanc
first time factset consensu updat financi model
beat outlook increas ep estim
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
sever potenti risk posit invest thesi price target
restrict ban use antibacteri food-produc anim may
becom preval zoeti current sell antibacteri product govern
consum begun shift away consum prefer and/or govern
regul grow may affect zoetiss abil meet forecast
advers weather condit avail natur resourc could drive
price feed expens compon produc feed price rise
profit fall zoetiss custom may spend less anim health drug
lack new product launch and/or exist product fail gain market share
street good expect zoetiss new launch compani perform
line better expect could downsid risk number
macro factor weather feed price currenc could advers impact sale
earn zoeti off-set sinc global busi said macro factor
global could pressur earn
oper margin expans lower expect zoeti still gross margin
expans expect compani meet target and/or
margin improv seen to-dat sustain could downsid number
brand and/or gener competit key drug zoeti face competit could
headwind sale given larg number product portfolio compani
strong relationship custom see smaller type risk
bull bear base case analysi
use dcf multipl price-to-earnings analysi arriv bull bear case scenario
base analysi estim likelihood stock worth next
exhibit bull bear base case scenario analysi
exhibit catalyst event calendar
exhibit incom statement analysi
exhibit margin analysi
exhibit quarterli sale analysi
exhibit annual sale analysi
exhibit analysi
exhibit balanc sheet analysi
zoeti anim health compani focus discoveri develop manufactur commerci anim health medicin
diagnost vaccin across livestock companion anim zoeti focus eight core speci cattl swine poultri sheep
fish form part compani livestock segment dog cat hors manag compani companion anim
segment zoetiss five major product categori within segment anti-infect vaccin parasiticid medic feed addit
pharmaceut
